Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; circulatory restoration products for the treatment of calcified coronary artery and peripheral artery diseases; and neurovascular care that treats hemorrhagic and ischemic stroke. This segment offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Johnson & Johnson

Barclays analyst Matt Miksic maintained a Hold rating on Johnson & Johnson today and set a price target of $234.00. According to TipRanks, Miksic i...

Barclays Reaffirms Their Hold Rating on Johnson & Johnson (JNJ)

Market volatility has defined 2026 so far, with geopolitical tensions driving swings across the broader market. While the S&P 500 ($SPX) is down ab...

3 Vanguard ETFs Are Beating the S&P 500 in 2026 – Should You Buy?

Erste Group analyst Hans Engel maintained a Buy rating on Johnson & Johnson yesterday. The company’s shares closed yesterday at $243.04. Engel cove...

Erste Group Remains a Buy on Johnson & Johnson (JNJ)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Johnson & Johnson (JNJ) and BioNano Genomics (BNGO). Johnson & Jo...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Johnson & Johnson (JNJ) and BioNano Genomics (BNGO)

For investors aiming to grow their capital while markets remain unsettled by the worsening conflict in the Middle East, exchange-traded funds prese...

3 Best ETFs to Invest In, According to AI Analyst, 03/30/2026

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Incyte (INCY), Sanofi (SNYNF) and Johnson & Johnso...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Incyte (INCY), Sanofi (OtherSNYNF) and Johnson & Johnson (JNJ)

As investors continue to grapple with volatility amid geopolitical tensions, exchange-traded funds (ETFs) could be an attractive investment opportu...

Best ETFs to Invest In, According to AI Analyst, 3/26/2026

IHI, IHE, ARKG: Specialty Healthcare ETFs Offer Diversification and Growth to Investors

Although the ongoing conflict in the Middle East has left investors on constant alert, exchange-traded funds remain among the strongest tools to de...

3 Best ETFs to Invest In, According to AI Analyst, 03/16/2026

This article spotlights three ETFs with Outperform ratings and significant upsides, as flagged by TipRanks’ AI analysts.


	A	B	C	D
1	Symbol	Price	Change	Volume
2	JNJ	$241.30	0.00%	8.77M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	JNJ	$241.30	0%	8.77M
3
4
5
6

JNJ

JNJ

Get Johnson & Johnson Data in Excel

Get Johnson & Johnson Data in Excel